STTR Phase II: Dermatologist-level detection of suspicious pigmented skin lesions from high-resolution full-body images

STTR II 期：通过高分辨率全身图像对可疑色素性皮肤病变进行皮肤科医生级别的检测

• 批准号: 2335086
• 负责人: Davood Tashayyod
• 金额: $ 99.64万
• 依托单位: LUMO IMAGING LLC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2335086&HistoricalAwards=false
• 关键词: STTR; Phase; II; Dermatologist; level

This Small Business Technology Transfer (STTR) Phase II project includes early detection of skin cancers, resulting in better outcomes and a reduction in mortality and healthcare expenditures. Each year in the United States, nearly 5 million people are treated for skin cancer, with an annual cost estimated at $8.1 billion. Annual productivity losses are estimated to cost an additional $4.5 billion. There is a considerable health disparity in the diagnosis of skin cancer within the U.S.; The average wait time to see a dermatologist is currently 32.3 days but it varies greatly by location. Early detection reduces disfigurement by reducing the size and extent of surgical removal and reducing the side effects that late-stage patients experience from systemic therapies. Furthermore, the project increases the economic competitiveness of the U.S. This Small Business Technology Transfer (STTR) Phase II project is to productize a novel, pigmented, lesion analysis system for wide field-of-view images. The product will be built on a previously developed total body photography system and proof of concept lesion classification software as a medical device that was developed in Phase I. The dermatoscope-like resolution provides a solid foundation for a system that can automatically (without the involvement of a dermatologist) detect and classify various skin conditions in a clinical setting and/or a radiology center (similar to how mammograms are done). Skin cancers, including both melanomas and non-melanomas, are the most common types of cancer in the United States. Early-stage identification of suspicious pigmented lesions in primary care settings can lead to improved melanoma prognosis and a possible 20-fold reductions in treatment cost. This technology provides the healthcare system with a highly sensitive, specific, and economical means of providing annual skin cancer screening to all at risk individuals.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业技术转移（STTR）II期项目包括对皮肤癌的早期发现，从而导致更好的结果和死亡率和医疗保健支出的降低。每年，在美国，将近500万人接受了皮肤癌的治疗，估计为81亿美元。年度生产力损失估计造成了45亿美元的额外损失。在美国，诊断皮肤癌存在很大的健康差异。目前，平均等待皮肤科医生的时间为32.3天，但随着位置而变化很大。早期检测通过减少手术清除的大小和程度并减少后期患者从全身疗法中经历的副作用来减少毁容。此外，该项目提高了美国的经济竞争力，这一小型企业技术转移（STTR）II期项目是为广泛的视野图像生产一种新颖的，有色的病变分析系统。该产品将建立在先前开发的全体摄影系统和概念病变分类软件作为医疗设备上的证明。皮肤镜类似于皮肤镜的设备，类似皮肤镜的分辨率为可以自动（无需涉及皮肤科医生）自动检测和分类的系统的系统为稳固的基础提供了基础。包括黑色素瘤和非黑色素瘤在内的皮肤癌是美国最常见的癌症类型。在初级保健环境中对可疑色素病变的早期鉴定可以改善黑色素瘤的预后和治疗成本可能降低20倍。这项技术为医疗保健系统提供了高度敏感，特定和经济的手段，可为所有人提供年度皮肤癌筛查。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的智力优点和更广泛影响的评估评估的评估来支持的。